Orphazyme A/S Logo

Orphazyme A/S

ORPHA.CO

(0.5)
Stock Price

1.120,00 DKK

-135.61% ROA

-131.82% ROE

-1.88x PER

Market Cap.

53.850.192,00 DKK

0% DER

0% Yield

0% NPM

Orphazyme A/S Stock Analysis

Orphazyme A/S Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Orphazyme A/S Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's PBV ratio (2.84x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

2 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

3 ROE

Negative ROE (-198.94%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-366.23%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 DER

The company has a high debt to equity ratio (428%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Orphazyme A/S Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Orphazyme A/S Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Orphazyme A/S Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Orphazyme A/S Revenue
Year Revenue Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 36.193.000 100%
2022 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Orphazyme A/S Research and Development Expenses
Year Research and Development Expenses Growth
2015 45.865.000
2016 55.817.000 17.83%
2017 99.048.000 43.65%
2018 154.952.000 36.08%
2019 285.413.000 45.71%
2020 261.136.000 -9.3%
2021 229.942.000 -13.57%
2022 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Orphazyme A/S General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 7.220.000
2016 7.703.000 6.27%
2017 31.994.000 75.92%
2018 75.334.000 57.53%
2019 49.842.000 -51.15%
2020 342.199.000 85.43%
2021 421.443.000 18.8%
2022 41.241 -1021802.96%
2023 12.884 -220.09%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Orphazyme A/S EBITDA
Year EBITDA Growth
2015 -52.531.000
2016 -62.838.000 16.4%
2017 -130.456.000 51.83%
2018 -230.281.000 43.35%
2019 -331.914.000 30.62%
2020 -603.441.000 45%
2021 -615.302.000 1.93%
2022 -40.459.000 -1420.8%
2023 -12.102 -334216.64%
2024 -5.968.000 99.8%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Orphazyme A/S Gross Profit
Year Gross Profit Growth
2015 0
2016 -572.000 100%
2017 -746.000 23.32%
2018 -1.366.000 45.39%
2019 -3.802.000 64.07%
2020 -5.199.000 26.87%
2021 18.082.000 128.75%
2022 -782.000 2412.28%
2023 0 0%
2024 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Orphazyme A/S Net Profit
Year Net Profit Growth
2015 -47.714.000
2016 -57.935.000 17.64%
2017 -126.204.000 54.09%
2018 -229.600.000 45.03%
2019 -337.497.000 31.97%
2020 -633.246.000 46.7%
2021 -626.539.000 -1.07%
2022 -110.594.000 -466.52%
2023 -26.048 -424477.7%
2024 7.392.000 100.35%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Orphazyme A/S Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 -5
2016 -6 20%
2017 -10 50%
2018 -11 9.09%
2019 -16.873 99.93%
2020 -22.324 24.42%
2021 -17.940 -24.44%
2022 -3.136 -472.25%
2023 -744 -321.37%
2024 209 455.98%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Orphazyme A/S Free Cashflow
Year Free Cashflow Growth
2014 -36.996.000
2015 -46.909.000 21.13%
2016 -54.965.000 14.66%
2017 -96.917.000 43.29%
2018 -237.110.000 59.13%
2019 -330.103.000 28.17%
2020 -544.177.000 39.34%
2021 -603.565.000 9.84%
2022 -104.516.000 -477.49%
2023 -20.021 -521931.87%
2024 -289.000 93.07%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Orphazyme A/S Operating Cashflow
Year Operating Cashflow Growth
2014 -36.438.000
2015 -46.414.000 21.49%
2016 -54.727.000 15.19%
2017 -95.426.000 42.65%
2018 -234.764.000 59.35%
2019 -326.818.000 28.17%
2020 -539.076.000 39.37%
2021 -602.571.000 10.54%
2022 -104.516.000 -476.53%
2023 -20.021 -521931.87%
2024 -289.000 93.07%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Orphazyme A/S Capital Expenditure
Year Capital Expenditure Growth
2014 558.000
2015 495.000 -12.73%
2016 238.000 -107.98%
2017 1.491.000 84.04%
2018 2.346.000 36.45%
2019 3.285.000 28.58%
2020 5.101.000 35.6%
2021 994.000 -413.18%
2022 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Orphazyme A/S Equity
Year Equity Growth
2013 31.547.000
2014 89.380.000 64.7%
2015 74.143.000 -20.55%
2016 17.509.000 -323.46%
2017 615.702.000 97.16%
2018 388.249.000 -58.58%
2019 52.969.000 -632.97%
2020 620.525.000 91.46%
2021 9.339.000 -6544.45%
2022 40.974.000 77.21%
2022 78.205.000 47.61%
2023 14.242.000 -449.12%
2024 16.088.999 11.48%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Orphazyme A/S Assets
Year Assets Growth
2013 35.564.000
2014 95.347.000 62.7%
2015 84.952.000 -12.24%
2016 31.941.000 -165.97%
2017 662.817.000 95.18%
2018 441.349.000 -50.18%
2019 180.754.000 -144.17%
2020 822.493.000 78.02%
2021 173.229.000 -374.8%
2022 56.826.000 -204.84%
2022 93.589.000 39.28%
2023 19.312.000 -384.62%
2024 17.850.000 -8.19%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Orphazyme A/S Liabilities
Year Liabilities Growth
2013 4.017.000
2014 5.967.000 32.68%
2015 10.809.000 44.8%
2016 14.432.000 25.1%
2017 47.115.000 69.37%
2018 53.100.000 11.27%
2019 127.785.000 58.45%
2020 201.968.000 36.73%
2021 163.890.000 -23.23%
2022 15.852.000 -933.88%
2022 15.384.000 -3.04%
2023 5.070.000 -203.43%
2024 1.761.000 -187.9%

Orphazyme A/S Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-685.51
Price to Earning Ratio
-1.88x
Price To Sales Ratio
0x
POCF Ratio
-2.24
PFCF Ratio
-2.65
Price to Book Ratio
2.83
EV to Sales
0
EV Over EBITDA
-1.4
EV to Operating CashFlow
-1.96
EV to FreeCashFlow
-1.96
Earnings Yield
-0.53
FreeCashFlow Yield
-0.38
Market Cap
0,05 Bil.
Enterprise Value
0,04 Bil.
Graham Number
2650.94
Graham NetNet
452.91

Income Statement Metrics

Net Income per Share
-685.51
Income Quality
0.84
ROE
-1.32
Return On Assets
-1.36
Return On Capital Employed
-1.77
Net Income per EBT
1
EBT Per Ebit
0.85
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-575.27
Free CashFlow per Share
-575.27
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-1.77
Return on Tangible Assets
-1.36
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
502,78
Book Value per Share
455,62
Tangible Book Value per Share
455.62
Shareholders Equity per Share
455.62
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.49
Current Ratio
10.14
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,02 Bil.
Invested Capital
16089000
Working Capital
0,02 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
-549.5
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Orphazyme A/S Dividends
Year Dividends Growth

Orphazyme A/S Profile

About Orphazyme A/S

Orphazyme A/S does not have significant operations. Previously, the company was engaged in the development of therapies for the treatment of neurodegenerative rare diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

CEO
Mr. Jakob Færch Bendtsen
Employee
1
Address
Ole Maaløes Vej 3
Copenhagen, 2200

Orphazyme A/S Executives & BODs

Orphazyme A/S Executives & BODs
# Name Age
1 Mr. Jakob Færch Bendtsen
Chief Executive Officer & Director
70

Orphazyme A/S Competitors

Zealand Pharma A/S Logo
Zealand Pharma A/S

ZEAL.CO

(0.5)
Ambu A/S Logo
Ambu A/S

AMBU-B.CO

(0.5)
BioPorto A/S Logo
BioPorto A/S

BIOPOR.CO

(0.5)
Bavarian Nordic A/S Logo
Bavarian Nordic A/S

BAVA.CO

(3.0)
Genmab A/S Logo
Genmab A/S

GMAB.CO

(2.2)